Beyond the Jab: The Surprising New Frontiers of GLP-1 Therapy

When Ozempic and other GLP-1’s arrived, they had two uses: diabetes drugs and weight-loss jabs. However, over the past two years, a cascade of research has revealed that Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs), semaglutide, tirzepatide, liraglutide and others, appear to act on almost every organ system in the body. The implications are staggering, and forcing us to rethink chronic inflammatory disease from the ground up.

Here is what the evidence is telling us about the frontiers of GLP-1 therapy.

1. Dementia and Neuroprotection: A Complicated but Compelling Story

The brain is perhaps where the GLP-1 story gets most interesting, and most nuanced. GLP-1 receptors are expressed throughout the central nervous system, and the potential neuroprotective mechanisms are extensive:

Reduction of amyloid-β (Aβ) accumulation and tau hyperphosphorylation, the pathological hallmarks of Alzheimer's disease
Upregulation of Brain-Derived Neurotrophic Factor (BDNF), critical for neuronal survival and synaptic plasticity
Reduction of neuroinflammation via microglial modulation
Improvement of cerebral insulin signalling (the "type 3 diabetes" hypothesis of Alzheimer's)
Promotion of neurogenesis

Observational data is genuinely promising. A nested case-control study found GLP-1 RAs were associated with a 20% reduced odds of developing dementia (OR 0.80, 95% CI 0.74 to 0.88). A meta-analysis spanning 26 trials reported a significant reduction in dementia and cognitive decline in GLP-1-treated populations. In patients with Type 2 diabetes, liraglutide improved MMSE scores independently of weight loss or glycaemic control, suggesting a direct neuroprotective effect rather than a metabolic one.

But here is where we must be honest about the data. The phase 3 EVOKE and EVOKE+ trials, the largest and most rigorous test to date, tested semaglutide in over 3,000 patients with mild cognitive impairment or early Alzheimer's disease and found no difference in disease progression after 104 weeks compared to placebo.

How do we reconcile this? The most credible interpretation is that GLP-1 RAs may have their neuroprotective window of opportunity early, in pre-diabetic, metabolically vulnerable, or early-stage populations, rather than once established Alzheimer's pathology is already present. The Alzheimer's Association notes that liraglutide continues to show promise in improving cerebral blood flow and reducing inflammation, and next-generation GLP-1-based compounds are under active investigation.

The takeaway for functional medicine practice: GLP-1 RAs may be a powerful tool in the prevention of cognitive decline and vascular dementia, particularly in those with metabolic risk factors, insulin resistance, or early cognitive symptoms. Using them therapeutically in established Alzheimer's dementia appears to be a different and currently unsupported proposition.

2. NAFLD/MASH: Reversing the Silent Epidemic

Metabolic dysfunction-Associated Steatohepatitis (MASH), previously called NASH, is a rapidly growing cause of liver failure, yet has had almost no effective pharmacotherapy until very recently. The ESSENCE trial demonstrated that semaglutide achieved:

63% reduction in liver inflammation without worsening fibrosis, versus 34% with placebo
33% improvement in liver scarring versus 23% with placebo
Approximately double the rate of achieving both inflammation reduction and fibrosis improvement versus placebo

GLP-1 RAs appear to reduce hepatic steatosis, improve liver enzymes, and directly suppress hepatic inflammatory gene expression, effects that extend beyond what would be expected from weight loss alone.

3. Addiction and Substance Use Disorders: Quieting the Brain's Reward Circuit

One of the most striking anecdotal observations from early GLP-1 users was a near-complete loss of interest in alcohol, nicotine, and in some cases, recreational drugs. Science has now caught up to these reports.

GLP-1 receptors are expressed in the mesolimbic dopamine system, the brain's reward and craving circuitry. By modulating this pathway, GLP-1 RAs appear to reduce the reinforcing properties of addictive substances. A landmark study analysing electronic health records of 606,434 US veterans with Type 2 diabetes found that GLP-1 use was associated with:

14% reduced risk of developing any substance use disorder
18% reduction in alcohol use disorder
20% reduction in cocaine and nicotine use disorder
25% reduction in opioid use disorder

A separate small study in opioid use disorder found GLP-1 medication reduced opioid cravings by 40% over three weeks, with other data showing a 50% lower rate of alcohol intoxication in those on GLP-1s compared to controls.

Stanford researchers note that GLP-1s appear to "turn down the volume" of reward-seeking noise in the brain, whether that noise is driven by food, alcohol, drugs, or potentially other compulsive behaviours. Formal clinical trials for addiction indications are underway.

4. Polycystic Ovary Syndrome (PCOS): Addressing the Root, Not Just the Symptoms

PCOS is fundamentally a disorder of insulin resistance, hyperandrogenism, and chronic low-grade inflammation, all three of which are directly targeted by GLP-1 RAs. A 2025 meta-analysis of randomised controlled trials confirmed that GLP-1 RAs produce significant improvements in weight, insulin sensitivity, androgen levels, and menstrual regularity in women with PCOS.

GLP-1 receptors are expressed in ovarian tissue, and there is emerging evidence of direct ovarian effects beyond metabolic improvement. For the functional medicine practitioner managing PCOS, GLP-1 RAs represent a paradigm shift: a single agent addressing insulin resistance, weight, inflammation, and potentially ovulatory function simultaneously.

5. Kidney Disease: Organ Protection Beyond Glucose Control

The FLOW trial established semaglutide as kidney-protective, significantly reducing major renal events, cardiovascular events, and all-cause mortality in Chronic Kidney Disease (CKD) patients with diabetes, effects that appear to extend beyond glycaemic control.

The UK Kidney Association and the UK Renal Pharmacy Group now recommend GLP-1 RAs as a priority treatment for kidney patients, noting renal protection in large RCTs, safety across all CKD stages including dialysis, and the absence of renal metabolism meaning no dose adjustment is typically required.

Intriguingly, in lupus nephritis, where 10 to 20% of patients historically progress to end-stage renal disease within 5 years, a 2024 retrospective cohort study found patients not on GLP-1 RAs were 2.35 times more likely to develop end-stage renal disease or dialysis dependence at 5 years.

6. Rheumatic and Autoimmune Diseases: A New Conversation

Research has positioned GLP-1 therapies as "dual-action agents that not only improve cardiometabolic risk factors but may also influence disease activity and long-term outcomes for patients with autoimmune and inflammatory conditions." Specific signals include:

Rheumatoid arthritis and psoriatic arthritis: Potential disease-modifying effects via reduction of inflammatory cytokine expression
Osteoarthritis: Chondroprotective and anti-inflammatory properties, with clinically meaningful symptom improvements
Gout: Modest reductions in serum urate and weight-driven improvement in attack frequency
Glucocorticoid-treated patients: Cardiometabolic protection in those with steroid-induced metabolic complications

A note of caution: one observational study found an association with increased risk of certain autoimmune conditions, a signal worth monitoring as the evidence matures.

7. Cardiovascular Disease: The Foundation That Launched Everything

The cardiovascular benefits of GLP-1 RAs are now firmly established. The SELECT trial demonstrated that semaglutide reduced major adverse cardiovascular events (MACE) in obese patients without diabetes, confirming that the cardiovascular benefits extend beyond glycaemic or weight effects alone. Reductions in CRP, improvement in endothelial function, and anti-inflammatory effects on atherosclerotic plaques all appear to contribute.

The Unifying Thread: GLP-1 as a Systemic Anti-Inflammatory Agent

What connects all of these different conditions? The answer lies in the reach of GLP-1 receptors. These are not just pancreatic receptors, they are expressed on cells of the brain, gut, heart, kidney, immune system, mast cells, macrophages, T-regulatory cells, and vascular endothelium.

GLP-1 RAs, therefore, are not simply metabolic drugs that happen to have a few extra benefits. They appear to be systemic modulators of chronic inflammation, and chronic inflammation is the substrate underlying most of the conditions discussed above.

This reframes the clinical question. Rather than asking "Is my patient's HbA1c or BMI high enough to justify a GLP-1?", the question also becomes: "Does my patient have a chronic inflammatory condition rooted in metabolic dysregulation, mast cell activation, neuroinflammation, or immune dysregulation that might respond to GLP-1 pathway modulation?"

Important Caveats

This is a rapidly evolving field and intellectual honesty demands acknowledgement of its limitations:

Most non-metabolic indications are off-label. The evidence base for conditions like MCAS, addiction, and rheumatic disease, while exciting, is still early-stage, largely observational or small case series. Randomised controlled trials are pending or underway.
Not all patients tolerate GLP-1 RAs. GI side effects, gastroparesis risk, and potential pancreatitis risk remain important clinical considerations.
The Alzheimer's trial failure is a sobering reminder that mechanistic plausibility does not always translate to clinical benefit in advanced disease.
Some autoimmune risk signals exist and require careful monitoring.
Microdosing strategies for sensitive populations (like MCAS) require experienced clinical oversight.

Conclusion

The GLP-1 story is arguably the most exciting pharmacological development in medicine in a generation, not because these drugs are a silver bullet, but because they have opened a window into the deep interconnections between metabolism, inflammation, immunity, and neurological health.

From quieting overactive mast cells to reshaping the brain's reward circuitry to protecting kidneys in lupus, the frontier of GLP-1 medicine is expanding at a remarkable pace. As primary healthcare medicine practitioners, our job is to stay ahead of this evidence, apply it thoughtfully and individualise its use, while keeping our patients at the centre of every decision.

The evidence cited in this blog reflects the current state of research as of mid-2025/early 2026. Clinical application of off-label GLP-1 use should always be individualised and undertaken with appropriate clinical supervision.